New type of AI-Powered Data Fills Gaps Left By Clinical Trials

Dr. Michael R. Jaff, Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific and Dr. Peter Monteleone, MD, FACC, FSCAI an interventional cardiologist and vascular medicine physician at Ascension Texas Cardiovascular in Austin, Texas and principal investigator of the REAL-PE study talk about the study results and the potential for real-world data to improve patient care in pulmonary embolism treatment and beyond.

Michael R. Jaff, DO is the Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific. A former professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine. He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries. Dr. Jaff has published extensively in the field of Vascular Medicine with over 325 peer reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI).